West eyes growth from FDA biosimilar delivery flexibility
West Pharmaceutical Services expects significant growth from biosimilars as manufacturers use novel delivery devices as a “key differentiator”.
Archives for May 27, 2012
EMA okays MabThera after contamination at Roche site
The EMA has cleared the Roche oncology blockbuster MabThera after concluding contamination of API bioreactors poses little threat.